Multimodality Approaches to Treat Hypoxic Non-Small Cell Lung Cancer (NSCLC) Microenvironment

Genes and Cancer

Volumn 3, Issue 2, 2012, Pages 141-151

  Liang, Shuang ^a   Galluzzo, Paola ^a   Sobol, Anna ^a   Skucha, Sylvia ^a   Rambo, Brittany ^a   Bocchetta, Maurizio ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

insulin like growth factor 1 receptor signaling; notch signaling; tumor hypoxia

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CISPLATIN; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GAMMA SECRETASE INHIBITOR; MRK 003; PROTEIN KINASE B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; SURVIVAL TIME; TUMOR MICROENVIRONMENT;

MUS;

EID: 84869786847     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912457025     Document Type: Article

References (38)

1. Brown JM.Tumor hypoxia in cancer therapy.Methods Enzymol. 2007;435:297-321.
2. Keith B,Simon MC.Hypoxia-inducible factors, stem cells, and cancer.Cell. 2007;129:465-72.
3. Sahlgren C,Gustafsson MV,Jin S, et al.Notch signaling mediates hypoxia-induced tumor cell migration and invasion.Proc Natl Acad Sci U S A. 2008;105:6392-7.
4. DeYoung MP,Horak P,Sofer A, et al.Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.Genes Dev. 2008;22:239-51.
5. Gwinn DM,Shackelford DB,Egan DF, et al.AMPK phosphorylation of raptor mediates a metabolic checkpoint.Mol Cell. 2008;30:214-26.
6. Milas L,Hittelman WN.Cancer stem cells and tumor response to therapy: current problems and future prospects.Semin Radiat Oncol. 2009;19:96-105.
7. Chen Y,De Marco MA,Graziani I, et al.Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung.Cancer Res. 2007;67:7954-9.
8. Artavanis-Tsakonas S,Rand MD,Lake RJ.Notch signaling: cell fate control and signal integration in development.Science. 1999;284:770-776.
9. Lai EC.Notch cleavage: Nicastrin helps Presenilin make the final cut.Curr Biol. 2002;12:R200-2.
10. Mumm JS,Schroeter EH,Saxena MT, et al.A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1.Mol Cell. 2000;5:197-206.
11. Struhl G,Adachi A.Nuclear access and action of notch in vivo.Cell. 1998;93:649-60.
12. Miele L.Notch signaling.Clin Cancer Res. 2006;12:1074-1079.
13. Mammucari C,Tommasi di,Vignano A, et al.Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control.Dev Cell. 2005;8:665-76.
14. Graziani I,Eliasz S,De Marco MA, et al.Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway.Cancer Res. 2008;68:9678-85.
15. Gustafsson MV,Zheng X,Pereira T, et al.Hypoxia requires notch signaling to maintain the undifferentiated cell state.Dev Cell. 2005;9:617-28.
16. Eliasz S,Liang S,Chen Y, et al.Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway.Oncogene. 2010;29:2488-98.
17. Konishi J,Kawaguchi KS,Vo H, et al.Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.Cancer Res. 2007;67:8051-7.
18. Landor SK,Mutvei AP,Mamaeva V, et al.Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms.Proc Natl Acad Sci U S A. 2011;108:18814-9.
19. Chandarlapaty S,Sawai A,Scaltriti M, et al.AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.Cancer Cell. 2011;19:58-71.
20. Vadysirisack DD,Ellisen LW.mTOR activity under hypoxia.Methods Mol Biol. 2012;821:45-58.
21. Noman MZ,Janji B,Kaminska B, et al.Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression.Cancer Res. 2011;71:5976-86.
22. Hu YL,Delay M,Jahangiri A, et al.Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.Cancer Res. 2012;72:1773-83.
23. Conley SJ,Gheordunescu E,Kakarala P, et al.Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.Proc Natl Acad Sci U S A. 2012;109:2784-9.
24. Stage IV NSCLC treatment. Bethesda, MD: National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/HealthProfessional/page11.
25. Riccio O,van Gijn ME,Bezdek AC, et al.Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2.EMBO Rep. 2008;9:377-83.
26. Wu Y,Cain-Hom C,Choy L, et al.Therapeutic antibody targeting of individual Notch receptors.Nature. 2010;464:1052-7.
27. Song LL,Peng Y,Yun J, et al.Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells.Oncogene. 2008;27:5833-44.
28. Dummler B,Tschopp O,Hynx D, et al.Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies.Mol Cell Biol. 2006;26:8042-51.
29. She QB,Halilovic E,Ye Q, et al.4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.Cancer Cell. 2010;18:39-51.
30. Hirai H,Sootome H,Nakatsuru Y, et al.MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.Mol Cancer Ther. 2010;9:1956-67.
31. Pollak M.The insulin and insulin-like growth factor family in neoplasia: an update.Nat Rev Cancer. 2012;12:159-69.
32. Gentech Biooncology. Available from: http://www.tarceva.com/docs/Indication_Announcement_Letter.pdf.
33. Pharma strategy blog. Available from: http://pharmastrategyblog.com/2009/12/pfizer-terminates-figitumumab-trial-in-lung-cancer-for-futility.html/.
34. Roepstorff K,Grandal MV,Henriksen L, et al.Differential effects of EGFR ligands on endocytic sorting of the receptor.Traffic. 2009;10:1115-27.
35. Yonesaka K,Zejnullahu K,Lindeman N, et al.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Clin Cancer Res. 2008;14:6963-73.
36. Chang MH,Ahn HK,Lee J, et al.Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.Cancer. 2011;117:143-51.
37. Yotsumoto F,Fukami T,Yagi H, et al.Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.Cancer Sci. 2010;101:2351-60.
38. Dong A,Gupta A,Pai RK, et al.The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through Hippo pathway co-activator YAP1 activation.J Biol Chem. 2011;286:18301-10.